Sign In
Buy AVIR
$4.70
-0.0400 (-0.84%)
At Close: Jul 31, 2026
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
03:14pm, Wednesday, 04'th Dec 2024
On Wednesday, Atea Pharmaceuticals, Inc. AVIR released Phase 2 study data from the regimen of bemnifosbuvir and ruzasvir for the hepatitis C virus infection that causes liver swelling and can lead to
Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
07:00am, Tuesday, 26'th Nov 2024
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
10:40am, Friday, 22'nd Nov 2024
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
01:14pm, Saturday, 09'th Nov 2024
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Jonae Barnes - SVP of Investor Relations and Corporate Communications Dr. Jea
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
04:05pm, Thursday, 07'th Nov 2024
Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4'24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver
BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
10:45am, Wednesday, 16'th Oct 2024
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Doximity (DOCS) have performed compared to their sector so far this year.
New Strong Buy Stocks for October 16th
10:01am, Wednesday, 16'th Oct 2024
CLPR, REE, HMY, AVIR and WPRT have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2024.
Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:37am, Friday, 04'th Oct 2024
Atea Pharmaceuticals (AVIR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earning
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
10:46am, Monday, 30'th Sep 2024
Here is how Atea Pharmaceuticals, Inc. (AVIR) and PetIQ (PETQ) have performed compared to their sector so far this year.
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
07:00am, Friday, 13'th Sep 2024
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
10:46am, Wednesday, 28'th Aug 2024
Here is how Atea Pharmaceuticals, Inc. (AVIR) and McKesson (MCK) have performed compared to their sector so far this year.
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway
07:00am, Wednesday, 28'th Aug 2024
New Data Further Elucidates Bemnifosbuvir's Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RN
